The eventual structure of any user fees that the generic industry may pay could be shaped to some degree by the makeup of the Senate's Health, Education, Labor and Pensions Committee, which would have responsibility for any user fee bills. So the presence of newly-elected Sen. Joe Manchin, D-W.Va., who has joined the panel at least for the rest of the year, is interesting.

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.